Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: ...

Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...

(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

Omeros announced that the company submitted a New Drug Application (NDA) to the FDA for approval of OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery. OMS302, added to ...

Please provide your email address to receive an email when new articles are posted on . A novel intraocular ring provides good centration and stable holding of IOLs in the capsular bag, while ...

There is a small risk of needing further surgical treatment (such as IOL replacement implanted by a different one or surgery to improve vision) after the implantation of the initial IOL. A toric IOL ...

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan ...

RxSight reported preliminary Q4 results, capping off a record year for growth where sales climbed by approximately 82%. The company is capturing strong demand for its adjustable intraocular lens ...

TORONTO, Feb. 1, 2021 /CNW/ - Alcon, the global leader in eye care, is pleased to announce a nationwide launch of the Clareon ® intraocular lens (IOL) with the AutonoMe ® delivery system in Canada.

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care announced AcrySof® IQ Vivity®, a first-of-its-kind intraocular lens (IOL) is now commercially available in select European ...